Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia.

Introduction: Nelarabine, a prodrug of arabinosylguanine has lineage-specific toxicity for T lymphoblasts and is used to treat refractory or relapsed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma patients. The most commonly observed adverse effects associated with nelarabine are mainly hematological, i.e.

Silent cerebral infarct in sickle cell anemia patients of southern Turkey.

Background/aim: Silent cerebral infarct (SCI) is an ischemic lesion seen before clinical signs of brain infarct and ischemic changes in brain tissue. This study aimed to detect SCI with noninvasive methods and to determine related risk factors in patients with sickle cell anemia (SCA).

Materials And Methods: Fifty-four SCA patients who had no history of cerebral infarct and whose neurological examinations were normal were included in this study.

Are the Comments on HaNDL Syndrome in the ICHD-II Sufficient?

A 33-year-old man was admitted to our emergency department for severe frontal headache followed by a state of consciousness disturbance and right-sided hemiparesis. No previous febrile disease, head trauma, vascular risk factor, and medication for any systemic disease were defined in his history. He had experienced a similar disorder three years ago and had recovered completely.